Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.51 |
| ▸ | PTK2 | Q05397 | 5/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.41 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22792355 | 0.91 | PTGS2 (0.44) | PTGS2PTK2ATML3MBTL1VNN1 | |
| SCHEMBL22792315 | 0.89 | CA1 (0.43) | PTGS2PTK2ATML3MBTL1PTGDR | |
| SCHEMBL22792051 | 0.85 | PTGS2 (0.55) | PTGS2 | |
| SCHEMBL22792194 | 0.82 | TSHR (0.50) | ATML3MBTL1ALDH1A1TSHR | |
| SCHEMBL22792292 | 0.80 | ALOX15 (0.44) | ALDH1A1TSHR | |
| SCHEMBL22792188 | 0.80 | BRAF (0.53) | — | |
| SCHEMBL22792343 | 0.78 | CA1 (0.45) | PTGS2ALDH1A1 | |
| SCHEMBL22792346 | 0.77 | PTGS2 (0.39) | PTGS2CCR1ALDH1A1TSHR | |
| SCHEMBL22792359 | 0.77 | CA1 (0.59) | — | |
| SCHEMBL22792621 | 0.76 | CYP1A2 (0.54) | L3MBTL1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020252229-A2 | INHIBITORS OF SARM1 | DISARM THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |